These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38457761)

  • 1.
    Battaglin F; Ou FS; Qu X; Hochster HS; Niedzwiecki D; Goldberg RM; Mayer RJ; Ashouri K; Zemla TJ; Blanke CD; Venook AP; Kabbarah O; Lenz HJ; Innocenti F
    J Clin Oncol; 2024 Jun; 42(16):1890-1902. PubMed ID: 38457761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
    Lenz HJ; Ou FS; Venook AP; Hochster HS; Niedzwiecki D; Goldberg RM; Mayer RJ; Bertagnolli MM; Blanke CD; Zemla T; Qu X; Wirapati P; Tejpar S; Innocenti F; Kabbarah O
    J Clin Oncol; 2019 Aug; 37(22):1876-1885. PubMed ID: 31042420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
    Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
    Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
    Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
    Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
    Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
    Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
    Nixon AB; Sibley AB; Liu Y; Hatch AJ; Jiang C; Mulkey F; Starr MD; Brady JC; Niedzwiecki D; Venook AP; Baez-Diaz L; Lenz HJ; O'Neil BH; Innocenti F; Meyerhardt JA; O'Reilly EM; Owzar K; Hurwitz HI
    Clin Cancer Res; 2022 Jul; 28(13):2779-2788. PubMed ID: 34965954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.
    Hsu HC; Liu YC; Wang CW; Chou WC; Hsu YJ; Chiang JM; Lin YC; Yang TS
    Cancer Med; 2019 Jul; 8(7):3437-3446. PubMed ID: 31090176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
    Innocenti F; Ou FS; Qu X; Zemla TJ; Niedzwiecki D; Tam R; Mahajan S; Goldberg RM; Bertagnolli MM; Blanke CD; Sanoff H; Atkins J; Polite B; Venook AP; Lenz HJ; Kabbarah O
    J Clin Oncol; 2019 May; 37(14):1217-1227. PubMed ID: 30865548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.
    Bai L; Wang F; Li ZZ; Ren C; Zhang DS; Zhao Q; Lu YX; Wang DS; Ju HQ; Qiu MZ; Wang ZQ; Wang FH; Xu RH
    Medicine (Baltimore); 2016 Dec; 95(51):e4531. PubMed ID: 28002313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.
    Seligmann JF; Hatch AJ; Richman SD; Elliott F; Jacobs B; Brown S; Hurwitz H; Barrett JH; Quirke P; Nixon AB; Seymour MT
    JAMA Oncol; 2018 Apr; 4(4):564-568. PubMed ID: 29075780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
    Clarke SJ; Burge M; Feeney K; Gibbs P; Jones K; Marx G; Molloy MP; Price T; Reece WHH; Segelov E; Tebbutt NC
    PLoS One; 2020; 15(3):e0229900. PubMed ID: 32142532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
    Innocenti F; Sibley AB; Patil SA; Etheridge AS; Jiang C; Ou FS; Howell SD; Plummer SJ; Casey G; Bertagnolli MM; McLeod HL; Auman JT; Blanke CD; Furukawa Y; Venook AP; Kubo M; Lenz HJ; Parker JS; Ratain MJ; Owzar K
    Clin Cancer Res; 2021 Jan; 27(1):267-275. PubMed ID: 32958699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
    Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S
    Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
    Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.